Exelixis (EXEL) News
NASDAQ: EXELHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
64.63-1.20 (-1.82%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
EXEL news summary
We found 50 recent headlines mentioning Exelixis (EXEL): 6 in the past week and 29 in the past 30 days, most often from Nasdaq, Seeking Alpha, Business Wire. For price context, EXEL is down 1.82% at $64.63. The most recent story, "Exelixis (EXEL) is a Top-Ranked Momentum Stock: Should You Buy?", was published by Nasdaq on Nov 20, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Exelixis headlines
- Exelixis (EXEL) is a Top-Ranked Momentum Stock: Should You Buy?Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.Nasdaq
- Exelixis: Management's $5 Billion Aspiration Is Already In The Share PriceSeeking Alpha
- Exelixis Eyes Q1 Zanza Data as It Plans Beyond CABOBristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own StockExelixis (NASDAQ:EXEL) is preparing for a transition from a company built around its CABO franchise to one with…Nasdaq
- Exelixis, Inc. (EXEL) Presents at Jefferies Global Healthcare Conference 2026 TranscriptSeeking Alpha
- Exelixis, Inc. (EXEL) Presents at UBS Global Biopharma Conference 2026 TranscriptSeeking Alpha
- Where Will Exelixis Be in 5 Years? 1 Experimental Drug Could Change EverythingKey PointsCabometyx’s sales keep growing, but generic competition looms by the end of the decade.NasdaqEXEL, BIO.B
- Exelixis Has 2 Major Catalysts Coming by March 2027. Here's What Investors Should Watch.Key PointsExelixis’ cabozantinib, addressing various types of cancer, has driven tremendous growth over the past 10 years.NasdaqEXEL, PFE
- XBI, SYRE, EXEL, BIIB: ETF Outflow AlertLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the State Street SPDR S&P Biotech ETF (Symbol: XBI) where we have…NasdaqXBI, SYRE, EXEL, BIIB
- Forget clinical cash burns: Why Exelixis is up 38% since JuneInvesting.com
- Exelixis Nears FDA Decision, Key Kidney Cancer Data for ZanzalintinibBristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own StockExelixis (NASDAQ:EXEL) is preparing for a regulatory decision on its cancer drug candidate zanzalintinib and…Nasdaq
- Exelixis, Inc. (EXEL) Presents at Stifel 2026 Healthcare Conference 2026 TranscriptSeeking Alpha
- Exelixis Bets on Zanza as Next Cancer Franchise as FDA Decision NearsBristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own StockExelixis (NASDAQ:EXEL) is working to build its next cancer drug franchise around zanzalintinib, or zanza, while…Nasdaq
- Exelixis, Inc. (EXEL) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference TranscriptSeeking Alpha
- Here's Why Exelixis (EXEL) is a Strong Growth StockWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.Nasdaq
- The Top 5 Biotech Stocks I'd Buy Right Now Without Any HesitationKey PointsThese five biotechs all have promising late-stage pipeline candidates.NasdaqVRTX, GILD, EXEL, AMGN
- Exelixis (EXEL) International Revenue in Focus: Trends and ExpectationsEvaluate Exelixis' (EXEL) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.Nasdaq
- EXEL Q3 Earnings Beat Estimates on Strong Cabometyx SalesExelixis tops Q3 2026 earnings and revenue estimates as Cabometyx sales grow, share repurchases accelerate and its zanzalintinib pipeline advances.NasdaqEXEL, MRK
- Exelixis (EXEL) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- Exelixis, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate UpdatesExelixis, Inc. reported its financial results for the third quarter of 2026, with total revenues reaching $658.7 million, compared to $597.8 million for the same period in 2025. Net product revenues…NasdaqEXEL, MOG.B
- Exelixis outlines March 3, 2027 PDUFA for zanza while advancing Wave 2 pivotal plansSeeking Alpha
- Exelixis, Inc. (EXEL) Q3 2026 Earnings Call TranscriptSeeking Alpha
- What Exelixis (EXEL) Said on Its Q3 Earnings CallBristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own StockExelixis (NASDAQ:EXEL) reported third-quarter 2026 revenue of approximately $659 million, supported by continued…Nasdaq
- Exelixis, Inc. 2026 Q3 - Results - Earnings Call PresentationSeeking Alpha
- Exelixis (EXEL) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesAlthough the revenue and EPS for Exelixis (EXEL) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall…Nasdaq
- Exelixis (EXEL) Surpasses Q3 Earnings and Revenue EstimatesExelixis (EXEL) delivered earnings and revenue surprises of +5.62% and +0.86%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqEXEL, NTLA
- Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate UpdateALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2026, provided an update on progress toward achieving key corporate…Business Wire
- IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?IDEAYA Biosciences (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.NasdaqIDYA, EXEL
- Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own StockGLP-1 agonists may have taken up most of the attention when it comes to game-changing drugs in the last couple of years, but the oncology landscape is heating up as well, and investors may see a…NasdaqBMY, EXEL
- Forget the FDA Delay: 3 Reasons Exelixis Is Still a BuyKey PointsRegulators in the U.S. extended the review period for Exelixis’ request to approve a new cancer drug.Nasdaq
- Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseExelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.NasdaqEXEL, BIIB
- Why Exelixis (EXEL) is a Top Growth Stock for the Long-TermWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.Nasdaq
- Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2026 financial results will be released on Thursday, October 29, 2026, after the markets close.…Business Wire
- Why Exelixis (EXEL) is Poised to Beat Earnings Estimates AgainExelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.Nasdaq
- Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law FirmNEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of EXELIXIS, Inc. (NASDAQ: EXEL) breached their…PR Newswire
- Here's Why Exelixis (EXEL) is a Strong Value StockWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.Nasdaq
- Biotech Stocks At 52-Week Highs - PGEN, EXEL, TWST, HNGE, PBYI(RTTNews) - The following biotech stocks reached a 52-week high on September 30, 2026, driven by key catalysts such as promising results from clinical trials.NasdaqEXEL, HNGE, PBYI, PGEN
- Exelixis (EXEL) is a Top-Ranked Growth Stock: Should You Buy?Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.Nasdaq
- Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?Exelixis faces a three-month FDA review delay for zanzalintinib, pushing the potential CRC decision to March 2027.NasdaqEXEL, MRK
- Here's Why Exelixis (EXEL) is a Strong Momentum StockThe Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.Nasdaq
- Noteworthy ETF Inflows: XMHQ, MEDP, MANH, EXELLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Invesco S&P MidCap Quality ETF (Symbol: XMHQ) where we have detected…NasdaqXMHQ, MEDP, MANH, EXEL
- Alpha Teknova (TKNO) Moves 7.1% Higher: Will This Strength Last?Alpha Teknova (TKNO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near…NasdaqTKNO, EXEL
- Why Exelixis (EXEL) is a Top Value Stock for the Long-TermWondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.Nasdaq
- Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3BExelixis Reports Solid Earnings—Are New Highs Back on the Table?Exelixis (NASDAQ:EXEL) President and CEO Michael Morrissey said the company is focused on expanding its oncology franchises…Nasdaq
- Exelixis, Inc. (EXEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking AlphaEXEL, MS
- Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp HurdleExelixis Reports Solid Earnings—Are New Highs Back on the Table?Exelixis (NASDAQ:EXEL) executives outlined plans to continue expanding the CABOMETYX franchise while preparing for a potential…Nasdaq
- Exelixis: Why The 3-Month Delay Is More Negative Than It May Seem (Downgrade)Seeking Alpha
- Here's Why Exelixis (EXEL) is a Strong Growth StockWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.Nasdaq
- Exelixis Eyes CABOMETYX Growth, Zanzalintinib Catalysts Across Cancer FranchisesExelixis Reports Solid Earnings—Are New Highs Back on the Table?Exelixis (NASDAQ:EXEL) executives outlined a franchise-focused growth strategy centered on expanding CABOMETYX across renal cell…Nasdaq
- Exelixis: The FDA Delay Costs Less Than The Market ThinksSeeking Alpha
- Exelixis zanzalintinib NDA review extended three months by FDASeeking Alpha